LANSING, Mich., Jan. 2, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that, due to U.S. equity markets being closed in observance of the National Day of Mourning for former U.S. President Jimmy Carter, it will now issue its second-quarter earnings release before the opening of the market on Friday, January 10, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.
The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Call.
The live webcast can be accessed through Neogen's Investor Relations webpage, https://www.neogen.com/investor-relations/, under the "Events & Presentations" subheading.
A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed domestically or internationally by dialing (888) 660-6345 or +1 (646) 517-4150, respectively, and providing the entry code 39384# or through Neogen's Investor Relations website at https://www.neogen.com/investor-relations/.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
| Last Trade: | US$5.20 |
| Daily Change: | 0.22 4.32 |
| Daily Volume: | 1,881,180 |
| Market Cap: | US$1.130B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
